Human Breast Cancer, Triple Negative (ER-/PR-/Her2-), FFPE Sections

Human Triple Negative (ER-PR-HER2-) Breast Cancer is a specific subtype of breast cancer characterized by the absence of three distinct receptors: Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) in the cancer cells of the breast tissue.

In this subtype, the cancer cells do not exhibit receptors for estrogen, progesterone, or HER2. The absence of these receptors distinguishes Triple Negative breast cancer from other subtypes and has implications for treatment strategies. Since the cancer cells lack responsiveness to hormones like estrogen and progesterone, as well as the HER2 protein, hormone therapy and HER2-targeted therapies are not typically effective in treating Triple Negative breast cancer.

The identification of Triple Negative breast cancer is crucial in tailoring treatment plans, often involving chemotherapy as a primary mode of intervention. Research and understanding of the molecular characteristics of this subtype play a significant role in developing targeted therapies for individuals diagnosed with Triple Negative breast cancer.

VitroVivo Biotech provides Human Triple Negative (ER-PR-HER2-) Breast Cancer FFPE section to accelerate your breast cancer research. These human breast cancer FFPE sections are mounted on positively charged glass slides and sectioned at 5 µm thickness. These FFPE slides can be used to perform RNA scope ISH, FISH IF, IHC and NGS, etc.